EVRAS
ActiveSummary
EVRAS has been active since 1977 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €57,345 and a net result of €1,560. Equity is shrinking by about 9.3% per year across the filed financial years. Its solvency ranks better than 57% of 12,650 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Directors
Board 2
Day-to-day management 1
Permanent representatives 1
Not every act has been read: a resignation may still be missing
Mandate history
- Board
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| FINPHARMA |
|
| GESTIPHARMA |
|
Owners and capital
Owners
1 ownerChain of control
- UNIVERSAL PHARMA
- EVRAS
Highest known parent: UNIVERSAL PHARMA. The sources do not say who stands above it.
Owners 1
- UNIVERSAL PHARMAparent50.06%
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.